Healthcare Industry News: duodenal ulcer
News Release - October 8, 2006
Eisai Receives Summary Judgment Motion Decisions in U.S. Legal Action Over Aciphex(R) ANDA Filings
TEANECK, N.J., Oct. 8 (HSMN NewsFeed) -- Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) today announce that they received court decisions on ANDA-related summary judgment motions for Aciphex® (Active Ingredient Name: rabeprazole sodium, Product Name in Japan: Pariet®) on October 6, 2006 (U.S. Eastern time).Aciphex® has been shown to have a rapid onset of action and a reliable inhibitory effect on acid secretion related to duodenal ulcers and gastroesophageal reflux disease, which are confirmed in clinical studies. Aciphex® was launched in the U.S. in 1999 and is currently marketed worldwide.
About Aciphex
Aciphex® has a well-established safety profile. The most common side effect possibly related to Aciphex® is headache. Symptom relief does not rule out other serious stomach conditions. Patients on Warfarin (such as Coumadin®) may need to be monitored more closely by their doctor. For more information, visit www.aciphex.com or www.eisai.com.
Source: Eisai
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
